Palopegteriparatide is under clinical development by Ascendis Pharma and currently in Pre-Registration for Hypoparathyroidism. According to GlobalData, Pre-Registration drugs for Hypoparathyroidism have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Palopegteriparatide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Palopegteriparatide overview

Palopegteriparatide (Yorvipath) is a parathyroid hormone (PTH) replacement therapy. Yorvipath is formulated as solution for subcutaneous route of administration.  Yorvipath is indicated for the treatment of adults with chronic hypoparathyroidism.

Palopegteriparatide (ACP-014, TransCon PTH) is under development for the treatment of hypoparathyroidism. The drug candidate is a sustained-release long-acting prodrug of parathyroid hormone and is administered through subcutaneous route. The drug candidate acts by targeting parathyroid hormone receptor (PTH-R). It is developed based on the transcon technology.

Ascendis Pharma overview

Ascendis Pharma is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 ß/?, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rß/?) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company operates in the US, Germany and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.

For a complete picture of Palopegteriparatide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.